Seres Therapeutics, Inc.
MCRB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $168,517 | $97,143 | $121,842 | $127,994 |
| - Cash | $47,638 | $45,379 | $58,849 | $30,793 |
| + Debt | $85,253 | $87,434 | $89,548 | $91,640 |
| Enterprise Value | $206,132 | $139,198 | $152,541 | $188,841 |
| Revenue | $351 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$13,001 | -$1,059 | -$3,527 | $0 |
| % Margin | -3,704% | – | – | – |
| EBITDA | $9,263 | -$18,796 | $33,758 | -$14,552 |
| % Margin | 2,639% | – | – | – |
| Net Income | $8,204 | -$19,855 | $32,682 | -$15,637 |
| % Margin | 2,337.3% | – | – | – |
| EPS Diluted | 0.935 | -2.271 | 3.75 | -1.808 |
| % Growth | 141.2% | -160.6% | 307.5% | – |
| Operating Cash Flow | $2,206 | -$13,289 | $26,910 | -$38,882 |
| Capital Expenditures | -$8 | -$181 | -$34 | -$90 |
| Free Cash Flow | $2,198 | -$13,470 | $26,876 | -$38,972 |